Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

BPDCN: A Dermatologist's Perspective on Differential Diagnosis

Jesse Hirner

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

Treating Adults With Newly Diagnosed ALL

MyCancerHaven

R. Vij, A. Patel

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

5th SOHO Italy Annual Conference

H. Kantarjian